Paul Fields

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

Molecular imaging in drug development

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3D Slicer as an image computing platform for the Quantitative Imaging Network

Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphoma

Interim [¹⁸F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients

Idiopathic pulmonary fibrosis

18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging

The Emerging Hallmarks of Cancer Metabolism

¹⁸F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

Overview of early response assessment in lymphoma with FDG-PET

FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma

Role of Functional Imaging in the Management of Lymphoma

Revised Response Criteria for Malignant Lymphoma

Invasive diagnostic techniques in idiopathic interstitial pneumonias

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

¹⁸F-FDG PET/CT Imaging In Oncology

A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome

Role of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma

How I treat mycosis fungoides and Sézary syndrome

Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?

Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.

A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome

HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma

Diagnosis and Subtyping of De Novo and Relapsed Mediastinal Lymphomas by Endobronchial Ultrasound Needle Aspiration